• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    HeartSciences Inc. - Common Stock (NQ:HSCS)

    2.786 -0.084 (-2.93%)
    Streaming Delayed Price Updated: 3:59 PM EST, Feb 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about HeartSciences Inc. - Common Stock

    < Previous 1 2 3 Next >
    BioMedNewsBreaks — HeartSciences Inc. (NASDAQ: HSCS; HSCSW) Secures UWE As Exclusive ECG Education Reference Center
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
    Version 1.1 Designed to Provide Best Usability of any ECG System 
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces Conference Participation and Investor Webinar
    Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85 
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
    Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems 
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
    Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart disease 
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
    From HeartSciences Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
    Further expands HeartSciences extensive patent portfolio 
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Regains Compliance with Nasdaq Listing Requirements
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
    Granted Indian Patent for its MyoVista® Wavelet Technology 
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    News headline image
    HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
    Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease 
    From Heart Test Laboratories, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.